参考资料 [1]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 7.2024, June 26, 2024. [2]Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | New England Journal of...
三、2024 Version 3 版本在 2024 Version 2 版本的基础上做了如下调整: NSCL-18 ►新增脚注 II:FDA 批准的生物类似物是合适的替代选择。 参考文献 [1] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Non-Small Cell Lung Cancer, Version 3.2024, March 12, 2024....
[1]NCCN Guidelines Version 4.2024 Non-Small Cell Lung Cancer. [2]2022.《NCCN肿瘤学临床实践指南:非小细胞肺癌》 [3] FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer | FDA https://www.fda.gov/ne...
NSCL-J 6-6 ►新增参考文献 40:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol. 2023;34:S787-S788. 知识拓展 根据TRIDENT-1Ⅰ...
[1]NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1.2023. [2]Burnett H,Emich H,Carroll C,et al.Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer:A systematic literature review[J].PLoS One,...
NCCNGuidelinesVersion5.2024NCCNGuidelinesIndex TableofContents Non-SmallCellLungCancerDiscussion *GregoryJ.Riely,MD,PhD/Chair†ÞScottGettinger,MD†Þ*DwightH.Owen,MD,MSc† MemorialSloanKetteringCancerCenterYaleCancerCenter/SmilowCancerHospitalTheOhioStateUniversityComprehensive CancerCenter-JamesCancerHospital...
NCCN Guidelines Version 3.2011 Non-Small Cell Lung Cancer: NSCL-F 2/3. 持续维持:主要临床研究回顾 对KPS>80分的患者,吉西他滨维持治疗可显著延长生存13.1个月 研究 维持 中位 TTP/PFS 中位 OS Belani 2003 紫杉醇70mg/m 2 每周×3/4w vs. 观察 ...
Zhang L, Ou W, Liu Q, et al. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. Thorac Cancer 2014;5:50-56. 放疗同期化疗方案 NSCL-E 移除以下内容:序贯化疗/放疗方案(辅助) ...
Updates in version 2.2019 of the NCCN guidelines for non-small cell lung cancer from version 1.2019 NSCL-22 ALK rearrangement positive metastatic NSCLC:Lorlatinib added as a treatment option after progression on crizotinib and alectinib,brigatinib,or ceritinib.NSCL-23 ALK rearrangement positive ...
版本1.2021—2020年11月25日继续NCCNGuidelines版本1.2021非小细胞肺癌https://www.nccn.org/professionals/physician_gls/default.aspxNCCNhttps://www.nccn.org/professionals/physician_gls/default.aspxhttps://www.nccn.org/professionals/physician_gls/default.aspxGuidelineshttps://www.nccn.org/professionals/...